Research programme: antibody-coupled T-cell receptor therapeutics - Unum Therapeutics/Seattle Genetics

Drug Profile

Research programme: antibody-coupled T-cell receptor therapeutics - Unum Therapeutics/Seattle Genetics

Latest Information Update: 31 May 2016

Price : $50

At a glance

  • Originator Unum Therapeutics
  • Class Antibodies; T lymphocyte cell therapies
  • Mechanism of Action CD200 antigen inhibitors; Cell replacements; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 31 May 2016 Preclinical trials in Cancer in USA (Parenteral) before May 2016 (Unum's pipeline, May 2016)
  • 15 Mar 2016 Biomarkers information updated
  • 08 Jun 2015 Unum Therapeutics and Seattle Genetics agree to co-promote and co-develop antibody-coupled T-cell receptor (ACTR) therapies for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top